Patent · US Expired

Method for detecting the presence of G.sub.D3 ganglioside

US4507391A · kind A · utility

32Cited by
2References
12Claims
0Family size

Assignee

Inventors

Key dates

Filing dateApr 2, 1982
Grant dateMar 26, 1985
Priority date
Expiry dateApr 2, 2002

Classification

  • Technology area (CPC Y)Emerging Cross-Sectional Technologies
  • CPC primaryY10S436/828
  • WIPO fieldMeasurement
  • WIPO sectorInstruments

Abstract

Mouse monoclonal antibody AbR.sub.24 (Dippold et al., Proc. Natl. Acad. Sci. 77:6114-6118, 1980) has a high degree of specificity for human melanoma cells when tested on viable cultured cells using the PA-MHA serological assay. The antigen detected by this antibody has been isolated from melanoma cells and shown to be G.sub.D3 ganglioside by compositional and partial structural analysis and by comparison with authentic G.sub.D3 by thin layer chromatography (TLC). AbR.sub.24 reacts with authentic G.sub.D3, but not with any other ganglioside tested. Using TLC and reactivity with AbR.sub.24, a wide range of cells and tissues was examined for the presence of G.sub.D3. A new serological assay, termed glycolipid-mediated immune adherence (GMIA), was devised for assaying the reactivity of AbR.sub.24 with gangliosides. Melanomas (cultured cells or tumor tissue) were shown to have T.sub.D3 and G.sub.M3 as major gangliosides. Other cells and tissues examined also contained G.sub.D3, but usually only in low amounts. Melanomas (and MOLT-4, a T-cell line) were characterized by a simplified ganglioside profile with G.sub.D3 and G.sub.M3 as major components. The apparent discrepancy between the u…

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.